Investors & Media

About Regeneron

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.

Learn more about Regeneron 
Download our corporate fact sheet 
REGN October 2024 Corporate Presentation
Download our investor presentation

Press releases

Jan 13
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
Jan 13
Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial
Jan 13
Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
Visit our newsroom

Upcoming & recent events

Feb 4, 2025 8:30 AM EST

Regeneron Pharmaceuticals Q4 2024 Earnings Conference Call

Listen to webcast
View event details
Jan 13, 2025 5:15 PM EST

43rd Annual J.P. Morgan Healthcare Conference

Listen to webcast
View event details
Dec 5, 2024 9:30 AM EST

Piper Sandler 36th Annual Healthcare Conference

Listen to webcast
View event details
View investor events

Quarterly materials

Show all

Market Cap:

Jan 15, 2025 4:50 AM EST

Minimum 15 minutes delayed. Source: LSEG

Interactive analyst center

Interactive and downloadable financial data for investors and analysts.

View analyst center

Annual materials

2023 Regeneron Annual Report.
2023 Annual Report
2024 Regeneron Proxy Statement and Notice of Annual Shareholder Meeting.
2024 Proxy Statement
2023 Regeneron Year in Review.
Visit: 2023 Year in Review